

RE&D, Administration and Europe Office

Cisbio Bioassays
 Phone: +33 (0)4 66 79 67 05
 Fax: +33 (0)4 66 79 19 20
 E-mail: bioassays@cisbio.com

Japan Office

Sceiti Medical Labo K.K.
 Phone: +81 (0)3 5510 2932
 Fax: +81 (0)3 5510 0130
 E-mail: reagent@sctimedilabo.co.jp

USA Office

Cisbio US, Inc.
 Phone : 888 963 4567
 Fax : 781 687 1500
 E-mail : htrfinfo@cisbio.us



For in vitro research use only

Storage temperature: 2-8°C

www.htrf.com

HTRF® package insert

Document reference : 62STxPEJ rev10 (September 2009)

Packaging details:

| | | 384-well low volume plate (20 µL) |
|----------|-----------------------------|-----------------------------------|
| 62ST1PEJ | HTRF® KinEASE™-STK S1 jumbo | 100,000 tests |
| 62ST2PEJ | HTRF® KinEASE™-STK S2 jumbo | 100,000 tests |
| 62ST3PEJ | HTRF® KinEASE™-STK S3 jumbo | 100,000 tests |


1. Assay description and intended use

HTRF® KinEASE™-STK is a generic method for measuring Serine/Threonine kinase activities using three substrates and a universal detection system. More than 100 kinases can be tested with this kit (see Appendix).

The HTRF® KinEASE™-STK assay format involves the two steps described below:

1. Enzymatic step: During this step, the kinase will phosphorylate the substrate. The STK Substrate-biotin is incubated with the kinase. ATP is added to start the enzymatic reaction.


2. Detection step: The detection reagents will catch the phosphorylated substrate. The resulting TR-FRET signal is proportional to the phosphorylation level. The STK-Antibody labeled with Eu³⁺-Cryptate and streptavidin-XL665 are mixed in a single addition with EDTA (used to stop the kinase activity).



↓ Kinase
ATP



↓ EDTA
Detection reagents



Each KinEASE™ jumbo kit (cf § 9) contains the appropriate STK-substrate-biotin and is designed to allow 100,000 tests to be run at 20µL final volume, providing that the substrate final concentration in the enzymatic step is ≤ 900 nM and streptavidin/substrate ratio ≤ 1/4.

Some assay configurations may require additional Streptavidin-XL665 or STK Substrate vials which can be ordered separately. Please refer to HTRF® KinEASE™ product line (§9) for part number. For more information, contact your Cisbio representatives.

2. Kit description – Stock solution preparation

| Components | Quantity | | Stock solutions to prepare |
|--|-------------------------------------|---|---|
| STK Substrate 1, 2 or 3-biotin | 3 vials of 500 µg Lyophilized | ⇒ | Reconstitute with distilled water (refer to product label) to obtain a 500 µM stock solution |
| Streptavidin-XL665 | 5 vials of 3 mg Lyophilized | ⇒ | Reconstitute each vial with distilled water (refer to product label) to obtain a 16,67 µM stock solution in streptavidin |
| STK Antibody-Cryptate | 5 vials of 20,000 tests Lyophilized | ⇒ | Reconstitute each vial with 2 mL of distilled water to obtain the STK Antibody-cryptate stock solution* |
| 5x Enzymatic buffer HEPES 250 mM (pH7.0), NaN ₃ 0.1%, BSA 0.05%, Orthovanadate 0.5 mM | 5 vials of 50 mL Liquid 5x | | |
| HTRF Detection buffer HEPES 50 mM (pH7.0) with additives | 5 vials of 200 mL Liquid 1x | | |

Storage:

All kit components must be stored at +4°C until the expiration date printed on the product label.

After reconstitution, the stock solutions can be stored 1 week at +4°C or dispensed into single use aliquots and stored at -20°C.

*Cryptate conjugate working solution (prepared with frozen stock solution) should be filtered before use to improve assay reproducibility.

3. Additional material required (not provided)

| | Recommended Supplier* | Stock solution to prepare |
|---------------|---|--------------------------------|
| Kinase | Upstate (www.upstate.com) | Follow supplier's instructions |
| ATP | Sigma # A7699 | 5 mM in HEPES buffer 50 mM |

Enzymatic buffer supplements: The enzymatic buffer must be supplemented with any components required by the kinase of interest (See Appendix for further details).


| | Recommended Supplier* | Stock solution to prepare |
|-------------------------|-----------------------|-----------------------------|
| DTT | Sigma # D0632 | 100 mM in distilled water |
| CaCl₂ | Sigma # 21115 | 1 M (ready to use) |
| MgCl₂ | Sigma # M1028 | 1 M (ready to use) |
| AMP | Sigma # A1752 | 5 mM in distilled water |
| cGMP | Sigma # G6129 | 1 mM in distilled water |
| Lipid activator | Upstate # 20-133 | 10x solution (ready to use) |
| Calmodulin | Upstate # 14-368 | 100 µM in distilled water |

* Suppliers' names are indicative.

Storage: Stock solutions should be aliquoted and stored at -80°C for kinases and -20°C for ATP and DTT.

4. Assay protocol for 384w low volume plate (20µL)

Add assay components (working solutions) in the following order:



The kinase reaction is started by the addition of ATP (step 1) and is stopped by the addition of the detection reagents which contain EDTA (step 2). The incubation period for the enzymatic step is optimized depending on the kinase (§ 8.3).

For a 384w low volume plate, we recommend the 10 µL enzymatic step and the 10 µL detection step for a final assay volume of 20 µL. For a 96 half well plate (100 µL), each addition volume is simply multiplied by 5.

* For low volume compound addition, adjust volume to 4 µL with 1x kinase buffer. Keep DMSO ≤ 2% in the enzymatic step.

5. Preparation of the working solutions

The working solutions are prepared from stock solutions (§ 2-3) by following the instructions below:

| | Buffer to prepare |
|-------------------------------|--|
| Kinase buffer 1X | Dilute 1 volume of enzymatic buffer 5X with 4 volumes of distilled water and any supplements required by the kinase of interest, i.e. DTT, MgCl ₂ , CaCl ₂ , Calmodulin, etc. (see appendix) |
| HTRF® Detection buffer | Ready to use |

| | Component working solutions to prepare |
|---------------------------------------|--|
| Compounds | Dilute compound stock solution with kinase buffer to prepare a working solution which has 2.5X the required final concentration for the enzymatic step |
| STK Substrate 1, 2 or 3-biotin | Dilute the substrate stock solution (500 µM) with kinase buffer to prepare a working solution which has 5X the required final concentration for the enzymatic step |
| Kinase | Dilute the kinase stock solution with kinase buffer to prepare a working solution which has 5X the required final concentration for the enzymatic step |
| ATP* | Dilute the ATP stock solution (5 mM) with kinase buffer to prepare a working solution which has 5X the required final concentration for the enzymatic step |
| Sa-XL665** | Dilute the SaXL665 stock solution with HTRF® detection buffer to prepare a working solution which has 4X the required final concentration for the assay (20 µL) |
| STK-Antibody-Cryptate | Dilute the STK Antibody-Cryptate stock solution 1/50 with HTRF® detection buffer to obtain the working solution. (e.g. for 20,000 tests: 2 mL of STK Antibody-Cryptate stock solution + 98 mL of HTRF® detection buffer) |

* for an ATP 100 µM in the enzymatic step, prepare a 500 µM ATP working solution.

** for an Sa-XL665 125 nM final concentration, prepare a 500 nM SaXL665 working solution.

Precautions:

- Working solutions of STK Antibody-Cryptate and Sa-XL665 can be stored 1 week at +4°C.
- Other working solutions cannot be stored and must be used immediately.
- The enzyme working solution must be kept in an ice bath for the time of the experiment (to avoid degradation).
- HTRF® detection reagent concentrations have been set for optimal assay performances. Note that any dilution or improper use of the XL665 and Cryptate-conjugates will impair the assay's quality.

6. Kinase assay and controls

The kinase assay is performed as described below, using three different controls:

Negative control: used to calculate the specific signal. Appropriate Negative controls must be prepared for each Sa-XL665 concentration tested (§ 8.4).

Buffer control: used to make sure that buffers are not contaminated by Cryptate and do not generate any background fluorescence.

Cryptate control: used to check the Cryptate signal at 620 nm.

| | Kinase assay | Controls | | |
|--|--------------|--------------------|--------------------------|---------------------------|
| Enzymatic step (10 µL) | Sample | Negative | Cryptate | Buffer |
| Compounds (or kinase buffer) | 4 µL | 4 µL kinase buffer | 10 µL kinase buffer | 10 µL kinase buffer |
| STK Substrate 1, 2 or 3-biotin | 2 µL | 2 µL | | |
| Kinase | 2 µL | 2 µL kinase buffer | | |
| ATP | 2 µL | 2 µL | | |
| Seal plate and incubate at RT or 37°C | | | | |
| Detection step (10 µL) | | | | |
| Sa-XL665 | 5 µL | 5 µL | 5 µL detection buffer | 10 µL detection buffer |
| STK Ab-Cryptate | 5 µL | 5 µL | 5 µL | |
| Seal plate and incubate 1h at RT | | | | |
| Remove plate sealer and read on an HTRF® compatible reader* *More information at http://www.htrf.com/technology/htrfmeasurement/compatible_readers/ | | | | |

Data reduction:

The fluorescence is measured at 620 nm (Cryptate) and 665 nm (XL665). A ratio is calculated (665/620) for each well. Results are expressed as follows:

Specific signal = Ratio (Sample) – Ratio (Negative control)


Ratio = (665 nm/620 nm) x 10⁴

Mean ratio = Σ ratio/2 (n=2)

CV% = (Std deviation/Mean ratio)*100

7. Assay miniaturization and flexibility

When used as suggested, the kit contains sufficient reagents for 100,000 tests using a 384-well low volume plate in 20 µL final assay volume, providing that the substrate final concentration is ≤ 900 nM and streptavidin/substrate ratio ≤ 1/4.



Other plate formats (96-half-well or 1536-well) and final volumes (100 µL to less than 10 µL) can be used by simply proportionally adjusting each addition volume in order to maintain the concentrations as for the 20 µL final assay volume.

| Assay format: | Miniaturization | | |
|---------------------------------|---------------------------|-------------------------------------|-------------------------------|
| | 1536-well (10 μ L) | 384-well low volume (20 μ L) | 96 half-well (100 μ L) |
| Compounds/kinase/ Substrate/ATP | 2 / 1 / 1 / 1 μ L | 4 / 2 / 2 / 2 μ L | 20 / 10 / 10 / 10 μ L |
| Sa-XL665 | 2.5 μ L | 5 μ L | 25 μ L |
| STK-Ab-Cryptate | 2.5 μ L | 5 μ L | 25 μ L |
| Number of test per kit | 200,000 tests | 100,000 tests | 20,000 tests |

Plate references: 96 half-well plate (Costar # 3694 or equivalent), 384-well low volume plate (Greiner # 784076), 1536-well (Greiner #782086).

8. Optimization of the kinase assay

A typical development for a HTRF® KinEASE™-STK assay consists of the following steps:

1. Substrate selection (only possible with HTRF® KinEASE™-STK discovery kit)
2. Enzyme titration
3. Kinetic study
4. Substrate titration
5. ATP titration
6. Biotin/streptavidin ratio optimization
7. Inhibitor IC50 determination

Final concentrations of the assay components used for kinase assay optimization are :

| | | Conc. Max. | Conc. Min. |
|----------------------|---|----------------------------|--------------------------------|
| STK-Substrate-biotin | Final conc. in the enzymatic step (10 μ L) | 2 μ M | 0.97 nM |
| Kinase | | 10 ng/well (1 ng/ μ L) | 0.1 ng/well (0.01 ng/ μ L) |
| ATP | | 300 μ M | 1.7 nM |
| Sa-XL665 | Final conc. in the final assay volume (20 μ L) | 125 nM | 0.06 nM |
| STK-Ab-Cryptate | | Ready to use | Ready to use |

8.1. Substrate selection

The HTRF® KinEASE™-STK discovery kit which contains all 3 substrates allows the substrate selection test to be run.

This step is required for a given kinase not listed in Appendix.

To determine whether HTRF® KinEASE™-STK is suitable for the kinase of interest, the kinase should be tested with each substrate following the assay protocol described in §4. We recommend testing the kinase at the concentration of 10 ng/well* (384 half well plates, 20 μ L final volume) with STK substrate1, 2 or 3-biotin (1 μ M)*, and a saturating concentration of ATP (100 μ M)*. Allow the enzymatic reaction to run for 30 min at RT. Add the detection reagents. The biotin/streptavidin molar ratio must be 8/1 (i.e. 62.5 nM Sa-XL665**).

The enzymatic activity observed with one of the 3 peptides indicates the optimal substrate to use.

* Final concentrations in the enzymatic step (10 μ L).

** Final assay concentration (20 μ L).

8.2. Enzyme titration

This step allows the optimal enzyme concentration (for which the signal reaches 80% of the maximum) to be determined. A compromise may be found between a high assay signal and the enzyme consumption.

For this step, a fixed concentration of the STK-substrate-biotin (1 μ M) and ATP (100 μ M) should be tested with the following enzyme concentrations 10; 2; 1; 0.1 ng/well. Allow the enzymatic reaction to run for 30 mn. The biotin/streptavidin ratio of 8/1 must be used (i.e. 62.5 nM Sa-XL665).

8.3 Kinetic study

Enzyme kinetic depends on the kinase and substrate concentrations. A time course study is performed using a constant concentration of kinase (determined in the previous experiment), ATP (100 μM) and substrate (1 μM). The reaction is stopped at different end points by the addition of the detection reagents (1, 2, 5, 10, 15, 30, 60 min).

The biotin /streptavidin ratio must remain constant and equal to 8/1 (i.e. 62.5 nM Sa-XL665).

The signal is then plotted versus the different end points. Determine the linear part of the time course (correlation coefficient $R^2 > 0.99$) and from this section, the optimal incubation time to use for the next experiments.

8.4. Substrate titration

This step allows the determination of substrate K_m (app).

Use the optimal enzyme concentration (§ 8.2) and a saturating ATP concentration (100 μM). We recommend testing different STK substrate-biotin concentrations ranging from 2 μM to 0.97 nM (two fold serial dilutions). The kinase reaction is stopped at the previously determined optimal incubation period. During the detection step, it will be necessary to adjust the concentration of the SA-XL665 for each STK substrate-biotin concentration, in order to keep the biotin/streptavidin ratio constant at 8/1 as described in the following table. Furthermore, since the background may rise with increasing XL665 concentrations, it is necessary to run a negative control (no enzyme) for each Sa-XL665 concentration.

| STK Substrate-biotin | | Sa-XL665 |
|---|---------------------------------------|---------------------------------------|
| Final conc. in the enzymatic step (10 μL) | Final assay conc. (20 μL) | Final assay conc. (20 μL) |
| 2 μM | 1 μM | 0.125 μM |
| 1 μM | 0.5 μM | 62.50 nM |
| 0.5 μM | 0.25 μM | 31.25 nM |
| 0.25 μM | 0.125 μM | 15.61 nM |
| 0.125 μM | 62.50 nM | 7.81 nM |
| 62.50 nM | 31.25 nM | 3.90 nM |
| 31.25 nM | 15.61 nM | 1.95 nM |
| 15.61 nM | 7.81 nM | 0.97 nM |
| 7.81 nM | 3.90 nM | 0.48 nM |
| 3.90 nM | 1.95 nM | 0.24 nM |
| 1.95 nM | 0.97 nM | 0.12 nM |
| 0.97 nM | 0.485 nM | 0.06 nM |

The plot of the specific signal (ratio sample (with enzyme) – ratio negative) versus the substrate concentrations is then fitted to Michaelis-Menten or Lineweaver-Burke equations to calculate the substrate K_m (app).

8.5. ATP titration

This step allows the determination of ATP K_m (app).

Use the optimal enzyme concentration and a saturating STK-substrate-biotin concentration (1 μM).

We recommend testing ATP concentrations ranging from 300 μM to 1.7 nM (three fold serial dilutions). The kinase reaction is stopped at the optimal incubation period by adding the detection reagents. During the detection step, the biotin/streptavidin ratio must be fixed at 8/1 (62.5 nM SA-XL665). As in the previous step, the K_m (app) value must be determined from this experiment using either a Michaelis-Menten or a Lineweaver-Burke plot.

8.6. Biotin/streptavidin ratio optimization

The optimization of the biotin/streptavidin ratio is an important step which may lead to a substantial increase in signal.

Streptavidin-XL665 solutions are prepared in order to cover 2/1, 4/1, 8/1 biotin/streptavidin ratios. The test is run using the optimal enzyme, ATP and substrate concentrations (§ 8.1-5). Negative controls corresponding to each Sa-XL665 concentration must be used as this reagent has a direct contribution to the background level.

8.7 Inhibitor IC_{50} determination

The kinase activity is tested over a broad range of inhibitor concentrations to generate a dose response curve.

The test is generally run using the previously determined optimal assay conditions.

9. HTRF® KinEASE™ product line

The most appropriate HTRF® KinEASE™ assay system can be used depending on your specific applications (see table below).

HTRF® KinEASE™ kits consist of substrate(s)-biotin, antibody labeled with Europium Cryptate (Eu(K)), Sa-XL665, enzymatic and HTRF® detection buffers. Three packaging sizes are available using a 20 µL test format.

The kit discovery that includes the three STK substrates-biotin (1, 2 and 3) is designed to quickly test the desired Ser/Thr kinase. Once the substrate that works with the desired kinase has been identified, the kit S1, S2 or S3 including the most appropriate substrate can be used for kinase assay development (see appendix).

If larger volumes are required for HTS or profiling, kits are available in Bulk or Jumbo sizes. The kit reagents like substrate-biotin, Sa-XL665 and assay buffers can also be ordered separately.

HTRF® KinEASE™ for Serine / Threonine kinases

| Description | Quantity | Cat no. |
|--|---|----------------------------------|
| HTRF® KinEASE™-STK discovery (STK substrates 1, 2 and 3-biotin) | 1,000 tests | 62ST0PEB |
| HTRF® KinEASE™-STK S1 (STK substrate 1-biotin) | 1,000 tests Bulk 20,000 tests Jumbo 100,000 tests | 62ST1PEB 62ST1PEC 62ST1PEJ |
| HTRF® KinEASE™-STK S2 (STK substrate 2-biotin) | 1,000 tests Bulk 20,000 tests Jumbo 100,000 tests | 62ST2PEB 62ST2PEC 62ST2PEJ |
| HTRF® KinEASE™-STK S3 (STK substrate 3-biotin) | 1,000 tests Bulk 20,000 tests Jumbo 100,000 tests | 62ST3PEB 62ST3PEC 62ST3PEJ |
| STK substrate 1-biotin | 50 µg/vial 500 µg/vial | 61ST1BLE 61ST1BLC |
| STK substrate 2-biotin | 50 µg/vial 500 µg/vial | 61ST2BLE 61ST2BLC |
| STK substrate 3-biotin | 50 µg/vial 500 µg/vial | 61ST3BLE 61ST3BLC |

HTRF® KinEASE™ for Tyrosine kinases

| Description | Quantity | Cat no. |
|--------------------------|---|----------------------------------|
| HTRF® KinEASE™-TK | 1,000 tests Bulk 20,000 tests Jumbo 100,000 tests | 62TK0PEB 62TK0PEC 62TK0PEJ |
| TK substrate -biotin | 50 µg/vial 500 µg/vial | 61TK0BLE 61TK0BLC |

Companion products

| Description | Quantity | Cat no. |
|---|------------------------|----------------------------------|
| Sa-XL665 | 250 µg 1 mg 3 mg | 610SAXLA 610SAXLB 610SAXLG |
| 5x Enzymatic buffer HTRF® Detection buffer | 50 mL 200 mL | 62EZBFDD 62SDBRDF |

Terms and conditions of use

This product is the subject of one or more Patent applications licensed to Upstate, Ltd and used in a co-development agreement between Upstate Ltd. and Cisbio International. The purchase of this product conveys to the purchaser the non-transferable right to use the purchased amount of the product and components of the product for research use only conducted by the purchaser. For commercial purchasers using this product for research, the purchase of this product conveys to the purchaser the non-transferable right to use the purchased amount of the product and components of the product for a six (6) month evaluation period after the date of purchase for research use only. After the six (6) month evaluation period, the purchaser must contact Chemicon International, Inc. or Upstate Ltd. or its designee to obtain a commercial research license.

The purchaser cannot sell or otherwise transfer (a) this product (b) its components or (c) materials made using this product or its components to a third party or otherwise use this product or its components or materials made using this product or its components for any commercial purpose. The purchaser cannot use this product or its components in humans.

The purchaser may transfer information or materials made through the use of this product to a scientific collaborator, provided that such transfer is not for any commercial purpose, and that such collaborator agrees in writing (a) not to transfer such materials to any third party, and (b) to use such transferred materials and/or information solely for research and not for commercial purposes.

Commercial purposes means any activity by a party for consideration and may include, but is not limited to: (1) use of the product or its components in manufacturing; (2) use of the product or its components to provide a service, information, or data; (3) use of the product or its components for therapeutic, diagnostic or prophylactic purposes; or (4) resale of the product or its components, whether or not such product or its components are resold for use in research.

If the purchaser is not willing to accept the limitations of the limited use license, Upstate is willing to accept return of the products with a full refund. For information on commercial use of this product or obtaining a license to this product for purposes beyond non-profit research, contact the Intellectual Property department at Upstate at +001 951-676-8080 ext. 4274.